James Marken - ANI Pharmaceuticals Insider

ANI Pharmaceuticals -- USA Stock  

USD 61.14  0.50  0.82%

VP of Operations

Mr. James G. Marken is Vice President Operations of the Company. He has served as the Companys Vice President, Operations, since June 2013 and was promoted to Senior Vice President, Operations and Product Development in May 2016. Mr. Marken joined ANIP in March 2007 as General Manager of the Minnesota facilities. As Vice President, Operations and Product Development, Mr. Marken was principally responsible for the following areas manufacturing, packaging, engineeringmaintenance, purchasing, and warehousing. Mr. Marken brings over 20 years of pharmaceutical industry experience to the Company. Prior to joining ANIP in March 2007, he worked for Solvay Pharmaceuticals as plant manager and in various departments including quality control, validation and manufacturing
Age: 53  VP Since 2013      
218-634-3500  http://www.anipharmaceuticals.com
Marken holds a B.S. degree in Chemistry from Bemidji State University.

Management Efficiency

The company has return on total asset (ROA) of 6.74 % which means that it generated profit of $6.74 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of (0.63) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 201.51 M in liabilities with Debt to Equity (D/E) ratio of 115.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ANI Pharmaceuticals has Current Ratio of 3.29 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 2 records

VP Since

Marc KirchmeierVBI Vaccines
Naamit SherVascular Biogenics Ltd

Entity Summary

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota. ANI Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 173 people.ANI Pharmaceuticals (ANIP) is traded on NASDAQ General Markets in USA. It is located in MINNESOTA, U.S.A and employs 173 people. ANI Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

ANI Pharmaceuticals Leadership Team

Robert Brown, Chairman, MBA
Charlotte Arnold, President, MBA
Mark Ginski, President, Ph.D
Robert Schrepfer, VP, MBA
Daniel Raynor, Director
Stephen Carey, President
David Sullivan, VP, Ph.D
Karen Quinn, President
James Marken, VP
Peter Lankau, Director
Fred Holubow, Director
Tracy Marshbanks, Director
Arthur Przybyl, CEO
Thomas Penn, Director

Stock Performance Indicators

Current Sentiment - ANIP

ANI Pharmaceuticals Investor Sentiment
Most of Macroaxis users are presently bullish on ANI Pharmaceuticals. What is your sentiment towards investing in ANI Pharmaceuticals? Are you bullish or bearish?
98% Bullish
2% Bearish
Skip  Hide

BATS Exchange Efficient Frontier

Diversify in USA Market
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
Diversify Portfolios
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1) For any level of risk, select the one which has the highest expected return. 2) For any expected return, select the one which has the lowest volatility.
Diversify Portfolios
Check also Trending Equities. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.